Log in

Relevant bibliographies by topics / Venom immunotherapy / Journal articles

Journal articles on the topic 'Venom immunotherapy'

To see the other types of publications on this topic, follow the link: Venom immunotherapy.

Author: Grafiati

Published: 4 June 2021

Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Venom immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jovanovic, Dragana, Aleksandra Peric-Popadic, Sladjana Andrejevic, Igor Jovanovic, and Branka Bonaci-Nikolic. "Triple IgE-positivity to hornet, wasp and bee venom in the patient with anaphylaxis: Diagnostic and therapeutic approach." Vojnosanitetski pregled 76, no. 8 (2019): 839–42. http://dx.doi.org/10.2298/vsp160831144j.

Full text

Abstract:

Introduction. Triple-positivity (TP) or double-positivity (DP) for serum-specific immunoglobulin E (sIgE) antibodies against hornet venom (HV), wasp venom (WV) and/or honeybee venom (BV) causes significant problem in a selection of appropriate venom immunotherapy. However, DP/TP can be caused by cross-reactions resulting either from partial sequence identity of protein allergens in the venoms, or may be related to cross-reacting carbohydrate determinants (CCDs). Case report. A 60-year-old man was stung by a wasp and two days later by hornet. In both cases, within 15 minutes he developed hypotension and generalized urticaria and he was successfully treated with epinephrine, corticosteroids and fluids. After eight weeks, the examination revealed the negative skin prick test for all three venoms, but the sIgE-determination (ELISA, Biopharm) showed triple sensitization to native BV (0.55 IU/mL), WV (3.35 IU/mL) and HV (0.37 IU/mL). He was receiving the venom immunotherapy with venom mixtures for one year. In order to distinguish true multiple sensitization from cross-reactivity, the molecular-allergy testing by ImmunCAP with the CCD-free recombinant major allergens was performed. A high sensitization to Antigen 5-rVes v5 of WV (31.4 kU/L) was demonstrated while sIgE to phospholipase A2-rApi m1 of BV (0.15 kU/L) was negative; sIgE to CCDMUXF3- bromelain (0.75 kU/L) explained the sIgE-positivity for native BV. After these findings, a venom immunotherapy only with WV was initiated. Conclusion. In our patient, triple-IgE-positivity to native venoms detected by the ELISA was caused by cross-reactivity to CCDs. We recommend the molecular-allergy testing with the nonglycosylated recombinant allergens before starting the venom immunotherapy in patients with multiple-sIgE-positivity to native Hymenoptera venoms.

APA, Harvard, Vancouver, ISO, and other styles

2

Nittner-Marszalska, Marita. "Venom immunotherapy." Alergologia Polska - Polish Journal of Allergology 5, no. 2 (2018): 85–93. http://dx.doi.org/10.5114/pja.2018.76677.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Vervloet, D., and J. Birnbaum. "Venom immunotherapy." Revue Française d'Allergologie et d'Immunologie Clinique 38, no. 7 (January 1998): S243—S247. http://dx.doi.org/10.1016/s0335-7457(98)80107-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Church, Vernon M. "Venom Immunotherapy." Physician and Sportsmedicine 19, no. 8 (August 1991): 118–24. http://dx.doi.org/10.1080/00913847.1991.11702234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Brown, Simon. "Venom Immunotherapy." Allergy & Clinical Immunology International - Journal of the World Allergy Organization 18, no. 02 (2006): 48–51. http://dx.doi.org/10.1027/0838-1925.18.2.48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Golden, David B. K. "Venom Immunotherapy." Immunology and Allergy Clinics of North America 40, no. 1 (February 2020): 59–68. http://dx.doi.org/10.1016/j.iac.2019.09.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kholi-Wiesner, A., L. Stahlberger, C. Bieli, T. Stricker, and R. Lauener. "Bee venom allergy immunotherapy/wasp venom allergy immunotherapy." Reactions Weekly &NA;, no. 1407 (June 2012): 13. http://dx.doi.org/10.2165/00128415-201214070-00044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Venom immunotherapy interaction." Reactions Weekly &NA;, no. 990 (February 2004): 14. http://dx.doi.org/10.2165/00128415-200409900-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Bilò, Beatrice M., and Floriano Bonifazi. "Hymenoptera venom immunotherapy." Immunotherapy 3, no. 2 (February 2011): 229–46. http://dx.doi.org/10.2217/imt.10.88.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Golden, David B. K. "Discontinuing venom immunotherapy." Current Opinion in Allergy and Clinical Immunology 1, no. 4 (August 1, 2001): 353–56. http://dx.doi.org/10.1097/01.all.0000011038.45505.c6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Golden, David B. K. "Discontinuing venom immunotherapy." Current Opinion in Allergy and Clinical Immunology 1, no. 4 (August 2001): 353–56. http://dx.doi.org/10.1097/00130832-200108000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Graft, David F. "Maintenance venom immunotherapy." Current Opinion in Allergy and Clinical Immunology 2, no. 4 (August 2002): 359–62. http://dx.doi.org/10.1097/00130832-200208000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Lesourd, B., J. Paupe, M. Thiollet, R. Moulias, J. Sainte-Laudy, and P. Scheinmann. "Hymenoptera venom immunotherapy." Journal of Allergy and Clinical Immunology 83, no. 3 (March 1989): 563–71. http://dx.doi.org/10.1016/0091-6749(89)90067-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Lesourd, B., J. Paupe, M. Melani, J. Sainte-Laudy, R. Moulias, and P. Scheinmann. "Hymenoptera venom immunotherapy." Journal of Allergy and Clinical Immunology 83, no. 3 (March 1989): 572–80. http://dx.doi.org/10.1016/0091-6749(89)90068-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Oppenheimer, John, and David B. K. Golden. "Hymenoptera venom immunotherapy." Annals of Allergy, Asthma & Immunology 121, no. 3 (September 2018): 276–77. http://dx.doi.org/10.1016/j.anai.2018.06.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Richter, Jan, Gerhard Metzner, and Ulrich Behn. "Mathematical Modelling of Venom Immunotherapy." Journal of Theoretical Medicine 4, no. 2 (2002): 119–32. http://dx.doi.org/10.1080/10273660290022172.

Full text

Abstract:

Allergic hypersensitivity of type I for hymenoptera venoms is the most frequent reason for acute IgE-mediated anaphylactic reactions. The subcutaneous injection of increasing doses of purified allergen followed by long-term administration of an adequate maintenance dose over a period of 3–5 years called venom immunotherapy (VIT) has been proven to be a very effective treatment achieving protection in about 96% of allergic patients. Even though the principle of hyposensitisation has been introduced already 90 years ago, the underlying immunoregulatory mechanisms of VIT remain poorly understood. Recent studies suggest a shift in cytokine production from a Th2 to a Th1 cytokine profile during therapy. In this paper, a mathematical model for T-cell regulation and a model for mast cell/basophil desensitisation are presented and analysed to explain the mechanism of conventional rush and ultra-rush VIT.

APA, Harvard, Vancouver, ISO, and other styles

17

FISCHER, D., K. PAYTON, and J. BUTCHEY. "624 Rush venom immunotheraphy in patient with previous anaphylaxis during venom immunotherapy." Journal of Allergy and Clinical Immunology 97, no. 1 (January 1996): 338. http://dx.doi.org/10.1016/s0091-6749(96)80842-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Graft, David F. "Venom Immunotherapy During Pregnancy." Allergy and Asthma Proceedings 9, no. 5 (September 1, 1988): 563–65. http://dx.doi.org/10.2500/108854188778965546.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Bee venom allergy immunotherapy." Reactions Weekly &NA;, no. 1370 (September 2011): 9. http://dx.doi.org/10.2165/00128415-201113700-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

GOLDEN, D. "Discontinuation of venom immunotherapy." Journal of Allergy and Clinical Immunology 102, no. 4 (October 1998): 703. http://dx.doi.org/10.1016/s0091-6749(98)70297-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Scribner, Troy A., and David I. Bernstein. "Rapid venom immunotherapy update." Current Opinion in Allergy and Clinical Immunology 3, no. 4 (August 2003): 295–98. http://dx.doi.org/10.1097/00130832-200308000-00010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Pałgan, Krzysztof, Magdalena Żbikowska-Götz, Elżbieta Chrzaniecka, and Zbigniew Bartuzi. "Venom immunotherapy and pregnancy." Advances in Dermatology and Allergology 35, no. 1 (2018): 90–92. http://dx.doi.org/10.5114/ada.2018.73168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Bee venom allergy immunotherapy." Reactions Weekly &NA;, no. 1419 (September 2012): 11. http://dx.doi.org/10.2165/00128415-201214190-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Bee venom allergy immunotherapy." Reactions Weekly &NA;, no. 1423 (October 2012): 13. http://dx.doi.org/10.2165/00128415-201214230-00045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

GOLDEN, D., and H. SCHWARTZ. "Guidelines for venom immunotherapy." Journal of Allergy and Clinical Immunology 77, no. 5 (May 1986): 727–28. http://dx.doi.org/10.1016/0091-6749(86)90418-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Carneiro-Leão, Leonor, Luís Amaral, and Alice Coimbra. "Reasons for Declining Venom Immunotherapy." Acta Médica Portuguesa 31, no. 11 (November 30, 2018): 618. http://dx.doi.org/10.20344/amp.9695.

Full text

Abstract:

Introduction: Hymenoptera venom allergy is associated with significant morbidity and deterioration in health-related quality of life, and risk of fatal systemic reactions. Although venom immunotherapy is safe and the only effective treatment in allergic individuals, some patients prefer not to pursue this treatment. Since 2011, when the 50% reimbursement was stopped, patients must fully support the cost of immunotherapy. This study aimed to ascertain the reasons why patients decline immunotherapy.Material and Methods: A medical records review of all patients proposed to receive venom immunotherapy at an Allergy and Clinical Immunology Department in Porto, Portugal, between 2006 and 2015, followed by a phone interview to patients refusing treatment.Results: A total of 83 subjects were enrolled, with a mean (± SD) age of 44.4 (14.7) years and 55 (66%) males; 27 refused venom immunotherapy between 2006 and 2015. Nineteen were interviewed and 14 of those stated price as the main reason for declining treatment. The only identified risk factor associated with immunotherapy refusal was being proposed after 2011 (OR: 3.29; 95% CI: 1.12 – 9.68; p = 0.03).Discussion: The number of patients refusing venom immunotherapy doubled since reimbursement was withdrawn. Price was identified as the major obstacle to treatment completion. Immunotherapy proposal after reimbursement was stopped was associated with a 3-fold increase in the risk of refusing treatment.Conclusion: These findings show how economic decisions may have a detrimental effect on patient care, as immunotherapy refusal left them exposed to an avoidable life-threatening risk.

APA, Harvard, Vancouver, ISO, and other styles

27

Goldberg, Arnon, and Ronit Confino-Cohen. "Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy." Annals of Allergy, Asthma & Immunology 91, no. 4 (October 2003): 405–10. http://dx.doi.org/10.1016/s1081-1206(10)61689-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Golden, David B. K. "Practical Considerations in Venom Immunotherapy." Allergy and Asthma Proceedings 18, no. 2 (March 1, 1997): 79–83. http://dx.doi.org/10.2500/108854197778605518.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Santos, M. C. Pereira, M. L. Palma Carlos, E. Pedro, M. Branco Ferreira, A. Spinola, and A. G. Palma Carlos. "Specific immunotherapy with hymenoptera venom." Clinical and Applied Immunology Reviews 1, no. 3-4 (January 2001): 249–53. http://dx.doi.org/10.1016/s1529-1049(01)00013-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Mosbech, H., H. J. Malling, I. Biering, H. Böwadt, M. Søborg, B. Weeke, and H. Løwenstein. "Immunotherapy with Yellow Jacket Venom." Allergy 41, no. 2 (February 1986): 95–103. http://dx.doi.org/10.1111/j.1398-9995.1986.tb00284.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Magnan, A., V. Marin, L. Mély, J. Birnbaum, S. Romanet, P. Bongrand, and D. Vervloet. "Venom immunotherapy induces monocyte activation." Clinical & Experimental Allergy 31, no. 8 (August 2001): 1303–9. http://dx.doi.org/10.1046/j.1365-2222.2001.01171.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bilò, Beatrice M., and Floriano Bonifazi. "Advances in hymenoptera venom immunotherapy." Current Opinion in Allergy and Clinical Immunology 7, no. 6 (December 2007): 567–73. http://dx.doi.org/10.1097/aci.0b013e3282f1eca5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Bilò, M. Beatrice, Leonardo Antonicelli, and Floriano Bonifazi. "Purified vs. nonpurified venom immunotherapy." Current Opinion in Allergy and Clinical Immunology 10, no. 4 (August 2010): 330–36. http://dx.doi.org/10.1097/aci.0b013e328339f2d1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Gür Çetinkaya, Pınar, Saliha Esenboğa, Özge Uysal Soyer, Ayfer Tuncer, Bülent Enis Şekerel, and Ümit Murat Şahiner. "Subcutaneous venom immunotherapy in children." Annals of Allergy, Asthma & Immunology 120, no. 4 (April 2018): 424–28. http://dx.doi.org/10.1016/j.anai.2018.01.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Confino-Cohen, Ronit, Yossi Rosman, and Arnon Goldberg. "Rush Venom Immunotherapy in Children." Journal of Allergy and Clinical Immunology: In Practice 5, no. 3 (May 2017): 799–803. http://dx.doi.org/10.1016/j.jaip.2016.10.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Engin, Ayse, Fatma B. Oktelik, Aslı Gelincik, Aytul Sin, Betul A. Sin, Berna A. Dursun, Sengul Beyaz, Begum Gorgulu, Esin Cetin, and Gunnur Deniz. "The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice." Allergy and Asthma Proceedings 42, no. 4 (July 1, 2021): 350–56. http://dx.doi.org/10.2500/aap.2021.42.210024.

Full text

Abstract:

Background: Hymenoptera venom allergy is an immunoglobulin (Ig) E mediated hypersensitivity reaction to Hymenoptera venoms. Obvious identification of the culprit insect that causes the clinical symptoms and, hence, the accurate selection of venom for curative treatment, is of great importance for the effectiveness and safety of venom immunotherapy. Objective: In this study, the contribution of component-resolved diagnostics (CRD) is evaluated in the diagnosis of Hymenoptera venom allergy. Method: Ninety-three patients from four different centers in Turkey were included in the study. Conventional tests, including prick and intradermal skin tests, with commercial venom extracts and serum specific IgE (sIgE) levels for whole venoms were performed. An sIgE analysis for venom allergen components, including rApi m 1, rApi m 2, rApi m 10, rVes v 1, rVes v 5, were evaluated by immunoblotting. Results: In conventional test results, 17 of 35 patients with bee venom allergy were positive to honey bee venom, whereas 18 patients were positive to bee and wasp venoms. In 28 of 35 patients with bee venom allergy, the diagnosis was confirmed with CRD. CRD revealed a sensitivity of 80% in patients with bee venom allergy. According to conventional tests, 7 of 24 patients with vespid venom allergy demonstrated sensitivity only to Vespula species, whereas 17 patients revealed double positivity. The total diagnostic sensitivity of Ves v 1 and Ves v 5 was calculated as 87.5%. Ten of 23 patients with a history of hypersensitivity to both venoms showed double sensitivity with CRD; one patient had cross-reactivity, one patient was found to be sensitive only to bee venom, and, eight patients were sensitive only to Vespula species. Eleven patients had an uncertain history in terms of the culprit insect type and six of them had double sensitivity in CRD. Conclusion: CRD seemed to be more helpful in diagnosing vespid venom allergy than bee venom allergy. It can also discriminate clinically significant sensitizations from irrelevant ones.

APA, Harvard, Vancouver, ISO, and other styles

37

González-de-Olano, David, Iván Álvarez-Twose, Arantza Vega, Alberto Orfao, and Luis Escribano. "Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis." Immunotherapy 3, no. 5 (May 2011): 637–51. http://dx.doi.org/10.2217/imt.11.44.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Oren, Eyal, Soheil Chegini, and Daniel L. Hamilos. "Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy." Annals of Allergy, Asthma & Immunology 97, no. 5 (November 2006): 606–10. http://dx.doi.org/10.1016/s1081-1206(10)61088-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Patriarca, Giampiero, Eleonora Nucera, Chiara Roncallo, Arianna Aruanno, Carla Lombardo, Marzia Decinti, Lucilla Pascolini, Massimo Milani, Alessandro Buonomo, and Domenico Schiavino. "Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy." Journal of Allergy and Clinical Immunology 124, no. 2 (August 2009): 385. http://dx.doi.org/10.1016/j.jaci.2009.03.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Detjen, Paul, and Paul A. Greenberger. "Stinging Insect Allergy and Venom Immunotherapy." Allergy and Asthma Proceedings 14, no. 2 (March 1, 1993): 112–13. http://dx.doi.org/10.2500/108854193778812215.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Ochfeld, Elisa N., and Paul A. Greenberger. "Stinging insect allergy and venom immunotherapy." Allergy and Asthma Proceedings 40, no. 6 (November 1, 2019): 372–75. http://dx.doi.org/10.2500/aap.2019.40.4250.

Full text

Abstract:

The Hymenoptera order is divided into three families: Apidae, Vespidae, and Formicidae. Apidae include the honeybee, bumblebee, and sweat bee, which are all docile and tend to sting mostly on provocation. The Africanized killer bee, a product of interbreeding between the domestic and African honeybee, is very aggressive and is mostly found in Mexico, Central America, Arizona, and California. The yellow jacket, yellow hornet, white (bald) faced hornet, and paper wasp all belong to the Vespidae family. The Formicidae family includes the harvester ant and the fire ant. When a “bee” sting results in a large local reaction, defined as >10 cm induration and lasting > 24 hours, the likelihood of anaphylaxis from a future sting is approximately 5%. For comparison, when there is a history of anaphylaxis from a previous Hymenoptera sting and the patient has positive skin test results to venom, at least 60% of adults and 20‐32% of children will develop anaphylaxis with a future sting. Both patient groups should be instructed about avoidance measures and about carrying and knowing when to self-inject epinephrine, but immunotherapy with Hymenoptera venom is indicated for those patients with a history of anaphylaxis from the index sting and not for patients who have experienced a large local reaction. Immunotherapy is highly effective in that, by 4 years of injections, the incidence of subsequent sting-induced reactions is 3%. This incidence may increase modestly after discontinuation of injections but has not been reported to be > 10% in follow up.

APA, Harvard, Vancouver, ISO, and other styles

42

Jung, Betty C. "Selecting Patients for Insect Venom Immunotherapy." Annals of Internal Medicine 119, no. 5 (September 1, 1993): 437. http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Imbeau, Stephen A. "Selecting Patients for Insect Venom Immunotherapy." Annals of Internal Medicine 119, no. 5 (September 1, 1993): 437. http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Hatch, Richard T. "Selecting Patients for Insect Venom Immunotherapy." Annals of Internal Medicine 119, no. 5 (September 1, 1993): 437. http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

van der Linden, Peter-Willem G. "Selecting Patients for Insect Venom Immunotherapy." Annals of Internal Medicine 119, no. 5 (September 1, 1993): 437. http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Aberer, Werner, and Gunter Sturm. "Venom immunotherapy: pitfalls and open questions." Immunotherapy 3, no. 11 (November 2011): 1277–79. http://dx.doi.org/10.2217/imt.11.119.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Bilò, M. Beatrice, Leonardo Antonicelli, and Floriano Bonifazi. "Honeybee venom immunotherapy: certainties and pitfalls." Immunotherapy 4, no. 11 (November 2012): 1153–66. http://dx.doi.org/10.2217/imt.12.113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Golden, David B. K. "Insect sting allergy and venom immunotherapy." Annals of Allergy, Asthma & Immunology 96, no. 2 (February 2006): S16—S21. http://dx.doi.org/10.1016/s1081-1206(10)60897-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Hafner, Tomaz, Lawrence DuBuske, and Mitja Kosnik. "Long-term efficacy of venom immunotherapy." Annals of Allergy, Asthma & Immunology 100, no. 2 (February 2008): 162–65. http://dx.doi.org/10.1016/s1081-1206(10)60425-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Malling, H. J., R. Djurup, I. Søndergaard, and B. Weeke. "Clustered Immunotherapy with Yellow Jacket Venom." Allergy 40, no. 5 (July 1985): 373–83. http://dx.doi.org/10.1111/j.1398-9995.1985.tb00250.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!